Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, today announced the release of High Content Analyzer, the latest addition to the Genedata Screener® enterprise solution for high content screening (HCS) data analysis.
As screening scientists are confronted with ever increasing volumes of complex HCS data, visualization and analysis tools are required that ensure reliability, comparability and consistency of results from HCS experiments. The ability to interactively process, analyze, and review results throughout the workflow is also crucial for informed decision making and reliable hit list generation. Genedata Screener is an open, modular and scalable enterprise solution which addresses these screening demands. The Screener High Content Analyzer module combines HCS and HTS workflows in a single integrated application and provides a flexible and consistent solution for all screening processes.
High Content Analyzer features streamlined processing, systematic quality control and optimized management of HCS data. Due to its open architecture, it can flexibly capture and load assay data from any plate-based HCS instrument or image analysis software and can interface with in-house instrumentation and existing IT infrastructure. The collected information is then managed in a single application. Users can efficiently process multi-featured data sets ranging from one to over a thousand plates. Experimental problems can be quickly and automatically detected through a combination of built-in algorithms, summary statistics and targeted visualizations. Specific quality issues can be identified and remedied on the complete data set using drill-downs to original HCS images.
“The addition of the High Content Analyzer module further strengthens Genedata’s enterprise screening solution in the quickly emerging high content screening market,” said Dr. Othmar Pfannes, CEO of Genedata. “Genedata is proud to offer an integrated framework for both HTS and HCS activities that provides systematic data analysis and high-quality results.”
Genedata (genedata.com) develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata’s solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high throughput technologies. Solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan.